AltruBio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
AltruBio, Inc. - overview
Established
2020
Location
San Francisco, CA, US
Primary Industry
Biotechnology
About
Established in 2020 and based in California, US, AltruBio, Inc. , formerly known as AbGenomics Holding Inc. operates as a clinical-stage biotechnology that focuses on the discovery and development of targeted antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases. It has a R&D centre in Taipei.
The chairman and CEO of the company, Judy Chou graduated from Yale University and has worked in Bayer AG, Pfizer, and Medivation. In May 2024, the company raised USD 225 million in series B funding led by returning investor BVF Partners. The company mainly provides anti-immune inflammation drug ALTB-168, which is a humanized therapeutic target antibody. ALTB-168 can be used to treat diseases such as psoriasis, psoriatic arthritis, ulcerative colitis, and GVHD (Graft-versus-host disease).
AltruBio also provides immunity drug candidates ALTB-268, which can be used to treat ulcerative colitis and psoriatic arthritis. The company plans to use the funding to advance the clinical development of its novel immune checkpoint enhancer (ICE) PSGL-1 agonist antibody ALTB-268 and to support ongoing and planned Phase 2 clinical trials in ulcerative colitis.
Current Investors
CAM Capital, BVF Partners, aMoon
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.altrubio.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.